Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus

Abstract

Systemic lupus erythematosus induced by biologics mainly results from tumor necrosis factor-alpha remains unclear. The objectives of the study were to investigate the mechanisms of tumor necrosis factor-alpha inhibitor-induced systemic lupus erythematosus. Peripheral blood mononuclear cells obtained from thirteen psoriasis patients were cultured and treated with the following: untreated control, Streptococcus pyogenes with or without different biologics. The supernatants were collected for cytokines assay. Analysis of cytokine expression revealed that IL-2 and IL-10 levels decreased only in the TNF-α inhibitor-treated groups but not in the groups treated with biologics involving IL-17, IL-12/IL-23 or IL-23 inhibitor mechanisms (p < 0.001, p < 0.05). The IFN-γ/IL-13 ratio increased significantly in patients with SLE inducing biologics to S. pyogenes induction only compared with non-SLE inducing biologics to S. pyogenes induction only (p = 0.001). IL-2 and IL-10 depletion and a shift to the Th-1 pathway in the innate response are the correlated mechanism for tumor necrosis factor-alpha inhibitor-induced systemic lupus erythematosus.

Introduction

Biologics are widely used in treating moderate to severe psoriasis, psoriatic arthritis, rheumatoid arthritis, and hidradenitis suppurativa (1–4). Systemic lupus erythematosus (SLE) induced by biologics mostly occurs during the treatment of psoriasis with tumor necrosis factor-alpha (TNF-α) inhibitors, especially in patients with psoriatic and rheumatoid arthritis. TNF-α inhibitors were calculated with an odds ratio of 3.64 for SLE development (5). The onset of symptoms ranges from <1 month to more than 4 years. High antinuclear antibody (ANA) levels, double stranded DNA (dsDNA) autoantibody positivity, thrombocytopenia, leukopenia, hypocomplementemia, skin rash, and arthritis are relatively common symptoms in TNF-α inhibitor-induced SLE (TAILS) (6). Further pathological findings characterizing classical drug-induced lupus include an increased frequency of significant anti-dsDNA antibody titers and a decreased incidence of anti-histone antibodies (7). The incidence of TAILS in patients with ulcerative colitis/Crohn's, etc., is 0.5–1% (8). However, how anti-TNF-α agents induce autoantibody expression and lead to the development of SLE remain incompletely understood. Streptococcus pyogenes (S. pyogenes) can trigger the immune responses to activate psoriasis outbreaks (9, 10). Furthermore, the innate immune system has been shown to be activated by S. pyogenes in both guttate and chronic plaque psoriasis (11). The specific IgA response against to S. pyogenes was correlated with a cutaneous lymphocyte-associated antigen⁺ T-cell-depend IL-17F response (12). In this study, peripheral blood mononuclear cells (PBMCs) from psoriasis patients and S. pyogenes was used to challenge the PBMCs to simulate a real clinical psoriasis outbreak. We describe the cases of three patients with psoriasis who developed TAILS and investigated the underlying mechanisms. Two of these patients developed TAILS after treatment with adalimumab and one after treatment with etanercept. All three patients met the 1997 American College of Rheumatology (ACR) criteria for SLE.

Materials and Methods

Participants

Thirteen psoriasis patients with or without psoriatic arthritis and three healthy controls were enrolled in this study. All participants were selected from the clinic of the Dermatology or Rheumatology Departments of Taichung Veterans General Hospital. All participants provided written informed consent. The protocols and all research involving human participants were approved by the Institutional Review Board of Taichung Veterans General Hospital (TCVGH-CE16265B; TCVGH-CE20043B).

Materials

Streptococcus pyogenes group A was identified and provided by the Department of Pathology and Laboratory Medicine of Taichung Veterans General Hospital. After heat inactivation, S. pyogenes group A was placed on blood agar plates for 1 week.

Cell Culture

For PBMC culture, 16 mL of blood was collected from each patient in sodium citrate tubes (Vacutainer® CPT™, BD, USA), and PBMCs were purified through centrifugation over a density gradient. The cells were washed with PBS and subsequently cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C and 5% CO₂. S. pyogenes group A was prepared at a concentration of 2 × 10⁷ CFU/mL under the similar cell viability to normal control and proper immune induction response on PBMC (data not shown).

A total of 6 × 10⁵ cells per milliliter were then cultured in a 12-well plate and treated for 24 h with the following: control, S. pyogenes only, S. pyogenes + golimumab (0.5 μg per milliliter), S. pyogenes + ixekizumab (3.5 μg per milliliter), S. pyogenes + ustekinumab (0.25 μg per milliliter), S. pyogenes + adalimumab (4 μg per milliliter), S. pyogenes + secukinumab (16.7 or 34 μg per milliliter), S. pyogenes + guselkumab (1.2 μg per milliliter), and S. pyogenes + etanercept (1.9 μg per milliliter). Supernatants were collected for the subsequent measurement of cytokine levels. The concentrations of the biological agents we tested are the trough serum concentrations at a steady-state indicated in the pharmacokinetic section of the reference list.

Cell Viability Test

The separated peripheral blood mononuclear cells (PBMCs) were cultured using different concentrations of S. pyogenes for 24 h, and then, 0.5 mg per milliliter of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added. After reacting for 1 h, the mixtures were centrifuged and the supernatants were removed. Then, 200 μL of dimethyl sulfoxide was added to lyse the cells and dissolve purple crystals, and cell viability was analyzed using an enzyme-linked immunosorbent assay reader at a wavelength of 570 nm.

Multiplex Assay for Cytokine Levels

To measuring cytokine levels, culture supernatants were collected, and the concentrations of IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17A, IFN-γ, and TNF-α were determined using a protein multiplex immunoassay system (Bio-Plex Cytokine Array System, Bio-Rad Laboratories, Hercules, CA, USA). The IFN-γ/IL-13 ratio was calculated in different patients undergoing different biologics in vitro. If the patient uses this biological agent and eventually causes SLE, it can be classified into the SLE group. Conversely, if the patient uses another biological agent lead to eventually doesn't get SLE, it can be classified as a non-SLE group.

Statistical Analyses

All statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY, U.S.A.). Analysis of cytokine expression was with the use of the Mann-Whitney U test. The ratio of IFN-γ to IL-13 between TAILS-inducing biologics and non-TAILS-inducing biologics was analyzed with t-test. Data were presented as the mean ± standard deviation (SD). Two-sided P-values of 0.05 or less were considered to indicate statistical significance.

Results

Patients

Thirteen patients were enrolled in our study including, three of which developed TAILS that met the 1997 ACR criteria for SLE. Patients 1 and 2 received adalimumab for 6 and 47 months, respectively, whereas Patient 3 received etanercept for 24 months (Table 1). In addition, we assessed the patients' skin condition by using the Psoriasis Area and Severity Index (PASI). Patient 1's psoriasis worsened after adalimumab treatment from absolute PASI:15 to PASI:16; Patient 2's psoriasis was largely stable, going from PASI:3.8 to PASI:2; and Patient 3's psoriasis improved, going from PASI:26 to PASI:13 (Table 2). Of the three cases, Patient 1 experienced an outbreak of psoriasis and progressed to SLE most quickly. TNF-α inhibitor administration was subsequently discontinued for all three patients.

Response to Treatment

Patient 1 refused oral prednisolone and received ustekinumab for psoriasis and subsequently recovered in skin condition, going from PASI:16 to PASI:0.2. Patient 2 received secukinumab (150 mg per week), following which skin absolute PASI declined to 0. Patient 3 received Methotrexate (7.5 mg per week) for controlling psoriasis and thrombocytopenia, and skin absolute PASI was maintained to 18.2. ANA remained positive in all three cases. In addition, dsDNA autoantibody titer levels remained high in Patient 1 after 6 months of ustekinumab treatment. The level of the dsDNA autoantibody titer declined to normal in Patient 2 after only 2 months and after 1.5 years in Patient 3.

Cytokine Expression Analysis

The analysis of cytokine levels on psoriasis patients and healthy controls revealed no obvious difference (Supplementary Table S1). The analysis of cytokine expression treated with experienced or naïve biological agents revealed that IL-2 and IL-10 levels decreased in only the TNF-α inhibitor-treated groups but not in the groups treated with biologics involving inhibitor mechanisms for IL-17, IL-12/IL-23 or IL-23 (p < 0.001, p < 0.05, respectively; Figure 1). IL-2 and IL-10 levels also decreased in only the TNF-α inhibitor-treated groups but not in the groups treated with other biologics in healthy controls (Supplementary Table S1). The data between the concentration of IL-2 and TNF-α in vitro is a proportional correlation (Figure 2). We hypothesize that IL-2 secreting requires not only pathogens but also TNF-α, explaining IL-2 depletion in the presence of TNF-α inhibitors. The hypothesis needs more evidence to prove. The anti-IL-17 inhibitors, including ixekizumab and secukinumab, apparently did not attenuate IL-17, which could result from the action of different epitopes used for verifying the concentration in the multiplex assay and their blocking by biologics. In our thirteen patients, most of them experienced two or more biologics. Twenty-eight clinical treatment courses of biologics in total were as follows: adalimumab, 9; etanercept, 1; golimumab, 1; ustekinumab, 8; ixekizumab, 3; secukinumab, 5; and guselkumab, 1. The ratio of IFN-γ to IL-13 was significantly higher (p = 0.001) between after induction with S. pyogenes plus SLE-inducing biologics and after induction with S. pyogenes only than after induction with S. pyogenes plus non-SLE-inducing biologics and after induction with S. pyogenes only (Table 3; Figure 3). Because three patients with SLE were PSO + PSA, only four patients with PSO+PSA without SLE (P4, P6, P7, P8) were selected and the ratio of IFN-γ/IL13 was also significantly increased in the SLE group (p = 0.02; Supplementary Figure S1). This ratio could be used in the future for identifying the risk of TAILS. Taken together, low levels of TNF-α was correlated to low levels of IL-2. IL-2 and IL-10 depletion could create an environment for developing SLE. The ratio of IFN-γ/IL13 in SLE-inducing biologics was significantly higher than in non-SLE-inducing biologics.

Figure 1

Figure 2

Figure 3

Discussion

Decreased expression of IL-2 and IL-10 is associated with SLE development. A lack of IL-2 leads to the inhibition of activation-induced cell death and enhances the longevity of autoreactive T cells (13). Vaccinia recombinant viruses expressing the human IL-2 gene showed prolonged survival, decreased autoantibody in SLE mice (14). Limited IL-10 expression can increase the secretion of proinflammatory cytokines in pathogenic T cells and upregulate the presentation of antigens by dendritic cells to naïve T cells, thus promoting differentiation into pathogenic cells (15). Yin et al. (16) discussed the protective role of IL-10 in the development of lupus. They found that IL-10 depletion was closely related to severe and early-onset lupus and was also associated with IFN-γ production and an increased serum concentration of anti-dsDNA autoantibodies, similar to our observations in patients with TAILS.

As a chronic autoimmune disease, SLE is characterized by the presence of nuclear antigen autoantibodies. Recent studies have implicated innate immunity as a key switch for coordinating B cells, T cells, and macrophages in the pathogenesis of SLE (17). Innate immunity and the T_h1 reaction are major initiation responses against infections including streptococcus, staphylococcus, and various viruses. In a second aspect, cytokines involved in T_h2 immunity, including IL-4 and IL-13, counteract the T_h1 response. Macrophage polarization is a key step that drives the immune response toward either the M1 or M2 pathway. In the early stages of lupus, the M1 pathway is mediated by cytokines including IFN-γ, whereas the M2 pathway is mediated by IL-4 and IL-13. IFN-γ induction favors the production of M1 macrophages that are involved in inflammation and tissue damage. An increased concentration of IFN-γ can alter the ratio of T_h1 to T_h2 with predominance by T_h1 cells (18). In lupus immunopathology, IFN-γ is elevated in the serum of lupus patients, particularly those in the active stage (19). Th1/Th2 balance shift and elimination of IFN-gamma by IFN-γ targeting gene therapy was developed in treating SLE (20). However, the role of T_h2 immune responses in autoimmune development remains controversial, although it is known that IL-4 plays a crucial role in the Treg-mediated suppressive immune response. Plasma IL-4 concentrations were found to be significantly lower in SLE patients than in healthy controls (21). Furthermore, IL-4 can downregulate T_h1-mediated IgG subclasses of autoantibodies to prevent the development of lupus-like autoimmune disease (22). Although IL-13 is a strong anti-inflammatory cytokine that modulates macrophages, monocytes, and lymphocytes (23), a previous study found that plasma IL-13 levels were significantly higher in SLE patients than in controls (24). We hypothesize that different stages and timing are key factors governing the IL-13 concentration. Moreover, a disproportionate increase in IFN-γ or reduced IL-13 could be the mechanism in SLE. These differences could be due to possible feedback mechanism in vivo (24), which needs to be investigated by further or future studies. Alternatively, this could be due to different evolution—primary SLE and drug-induced SLE (TAILS).

In the present study, the IL-13 concentration increased within 24 h following the onset of inflammation caused by streptococcus infection. However, we are uncertain whether IL-13 promotes inflammation, rather than acting as a feedback cytokine that reduces inflammation. In our study, different biologics appeared to react differently to IL-13, but the detailed mechanisms remain unknown. In the three TAILS patients, we observed the lowest IL-13 concentrations for pathogenic drugs compared with other biologics including anti-IL-17, anti-IL-23, and other anti-TNF-α. IL-17 is apparently an important cytokine in the pathogenesis of SLE because it can amplify the immune response by increasing autoantibodies through B-cell stimulation (25). However, our data indicated no obvious differences in the IL-17 concentration between SLE and non-SLE groups. Anti-IL-17 inhibitors, including ixekizumab and secukinumab, apparently did not attenuate IL-17, which could result from the action of different epitopes used for verifying the concentration in the multiplex assay vs. blocking by biologics.

Adaptive transfer to M2 macrophages reduces the severity of SLE, whereas IL-4 and IL-13 drive the production of M2 macrophages (26). A similar condition was observed in innate lymphoid cells (ILCs). Group 2 ILCs produce IL-4, IL-9, and IL-13. Hou et al. found significantly reduced numbers of Group 2 ILCs in SLE patients (27). Restoring Group 2 ILCs with IL-33 reduced immune cell infiltration and improved survival in a mouse model (28). During outbreaks of psoriasis and SLE, the ratio of M1 to M2 macrophages is increased (26, 29). Other recent studies have highlighted M2 promotion and immunomodulation as another avenue for SLE treatment (30, 31). Hence, maintaining balance of M1/M2 and T_h1/T_h2 ratios is an ideal way to prevent SLE. Otherwise, IL-13 induction will favor the production of M2 macrophages that are involved in tissue repair.

In the present study, the data revealed that the three TAILS cases had high ratios of IFN-γ to IL-13 compared with those of biologics targeting other mechanisms in the same patients. Taken together with previous findings, our results suggest that the depletion of IL-2 and IL-10, along with the deterioration of the T_h1/T_h2 ratio, are potentially a major underlying mechanism for TAILS. To verify this, we analyzed the symptom severity of the three TAILS patients. Of the three cases, Patient 1's symptoms were the most severe, whereas Patient 2's was the least severe. Patients 1 and 3 were revealed to have low levels of IL-4, whereas Patient 2's IL-4 level was normal when compared with other biologics. Less deviation in the ratio of IFN-γ to IL-13 and a normal level of IL-4 could explain why Patient 2's symptoms were the least severe of the three patients. Hence, the degrees of deviation in the IFN-γ/IL-13 ratio and IL-4 impairment could be regarded as indicators of disease severity.

In the present study, we tested two types of anti-TNF-α (golimumab and adalimumab) in all three patients and an additional anti-TNF-α (etanercept) in Patient 3. The IFN-γ/IL-13 ratio in adalimumab and golimumab was 108.99 and 22.59, respectively, in Patient 1. The IFN-γ/IL-13 ratio in adalimumab and golimumab was 106.28 and 92.69, respectively, in Patient 2. The IFN-γ/IL-13 ratio in adalimumab, golimumab, and etanercept were 145.37, 114.5, and 167.68, respectively, in patient 3. These findings support the previous hypothesis that drug-induced SLE can be drug-specific rather than class-specific (6). Therefore, it is crucial to identify which patients will develop drug-induced SLE and what types of drugs will induce it. We believe the findings presented herein will provide a clear understanding for TAILS. We also believe the incidence of TAILS is underestimated.

Limitation

This study has some limitations. First, the results of the study need to be validated in a larger group to assess the variability and validity of our findings. Second, in vitro experiments on different cells line about cytokine expression, Th1/Th2 related cells subpopulation, and how the mechanisms of different biologics are affected by the IFN-γ or IL-13 concentration requires further investigation.

Conclusions

In conclusion, our results suggest that the underlying expression of TNF-α inhibitor-induced SLE correlates with depletion of IL-2 and IL-10 and T_h1/T_h2 related cytokine imbalance. Our findings provide a clearer understanding of SLE and suggest more appropriate treatments such as low-dose courses of IL-2 and IL-10. Although the sample sized analyzed was small, the observations in this study highlight possible mechanisms of etiology. However, more sample size researches are needed in the future.

Funding

This work was funded in part by the Chinese Medicine Research Center, China Medical University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (CMRC-CENTER-0). And also from Ministry of Science and Technology in Taiwan (MOST 109-2320-B-39-044). The funders had no role in study design, data collection and analysis, interpretation of findings, manuscript writing, and target journal selection.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1.

  MouradAIGniadeckiR. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med. (2020) 7:625755. 10.1016/j.jaad.2020.06.551

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  ChenHHLinCHWangCYChaoWC. Association of hospitalised infection with socioeconomic status in patients with rheumatoid arthritis receiving biologics or tofacitinib: a population-based cohort study. Front Med. (2021) 8:696167. 10.3389/fmed.2021.696167

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  ChiaAYTAngGWXChanASYChanWChongTKYLeungYY. Managing psoriatic arthritis with inflammatory bowel disease and/or uveitis. Front Med. (2021) 8:737256. 10.3389/fmed.2021.737256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  FrewJWSinghNJiangCSVaughanRKruegerJG. The impact of body mass index upon the efficacy of adalimumab in hidradenitis suppurativa. Front Med. (2021) 8:603281. 10.3389/fmed.2021.603281

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  HaugaardJHKofoedKGislasonGDreyerLEgebergA. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol. (2020) 156:1199–207. 10.1001/jamadermatol.2020.2786

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  WilliamsVLCohenPR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. (2011) 50:619–25. 10.1111/j.1365-4632.2011.04871.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  KatzUZandman-GoddardG. Drug-induced lupus: an update. Autoimmun Rev. (2010) 10:46–50. 10.1016/j.autrev.2010.07.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  LupuATieranuCConstantinescuCLDiculescuM. TNFalpha inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. Curr Health Sci J. (2014) 40:285–8. 10.12865/CHSJ.40.04.11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  MutoMFujikuraYHamamotoYIchimiyaMOhmuraASasazukiTet al. Immune response to Streptococcus pyogenes and the susceptibility to psoriasis. Australas J Dermatol. (1996) 37 (Suppl. 1):S54–55. 10.1111/j.1440-0960.1996.tb01087.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  GrootJBlegvadCNybo AndersenAMZachariaeCJarlovJOSkovL. Presence of streptococci and frequent tonsillitis among adolescents with psoriasis. Br J Dermatol. (2021) 184:758–9. 10.1111/bjd.19672

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  FryLBakerBSPowlesAVFahlenAEngstrandL. Is chronic plaque psoriasis triggered by microbiota in the skin?Br J Dermatol. (2013) 169:47–52. 10.1111/bjd.12322

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  De Jesus-GilCSans-De San NicolasLRuiz-RomeuEFerranMSoria-MartinezLChiriacAet al. Specific IgA and CLA(+) T-Cell IL-17 response to Streptococcus pyogenes in psoriasis. J Invest Dermatol. (2020) 140:1364–70.e1361. 10.1016/j.jid.2019.12.022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  TsokosGC. Systemic lupus erythematosus. N Engl J Med. (2011) 365:2110–21. 10.1056/NEJMra1100359

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  Gutierrez-RamosJCAndreuJLRevillaYVinuelaEMartinezC. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. (1990) 346:271–4. 10.1038/346271a0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  UchidaMOokaSGotoYSuzukiKFujimotoHIshimoriKet al. Anti-IL-10 antibody in systemic lupus erythematosus. Open Access Rheumatol. (2019) 11:61–5. 10.2147/OARRR.S191953

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  YinZBahtiyarGZhangNLiuLZhuPRobertMEet al. IL-10 regulates murine lupus. J Immunol. (2002) 169:2148–55. 10.4049/jimmunol.169.4.2148

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  HerradaAAEscobedoNIruretagoyenaMValenzuelaRABurgosPICuitinoLet al. Innate immune cells' contribution to systemic lupus erythematosus. Front Immunol. (2019) 10:772. 10.3389/fimmu.2019.00772

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  AkahoshiMNakashimaHTanakaYKohsakaTNaganoSOhgamiEet al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. (1999) 42:1644–8. 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  Al-JanadiMAl-BallaSAl-DalaanARaziuddinS. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. (1993) 13:58–67. 10.1007/BF00920636

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  HayashiT. Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J Biomed Biotechnol. (2010) 2010:461641. 10.1155/2010/461641

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  YuHHLiuPHLinYCChenWJLeeJHWangLCet al. Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus. (2010) 19:1219–28. 10.1177/0961203310371152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  SantiagoMLFossatiLJacquetCMullerWIzuiSReiningerL. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med. (1997) 185:65–70. 10.1084/jem.185.1.65

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  Hamzei TajSLe BlonDHoornaertCDaansJQuartaAPraetJet al. Targeted intracerebral delivery of the anti-inflammatory cytokine IL13 promotes alternative activation of both microglia and macrophages after stroke. J Neuroinflammation. (2018) 15:174. 10.1186/s12974-018-1212-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  WangRLuYLHuangHTQinHMLanYWangJLet al. Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus. Cytokine. (2018) 104:92–7. 10.1016/j.cyto.2017.09.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  LiDGuoBWuHTanLChangCLuQ. Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity. (2015) 48:353–61. 10.3109/08916934.2015.1037441

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  LiFYangYZhuXHuangLXuJ. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. (2015) 37:1279–88. 10.1159/000430251

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  HouMLiuS. Innate lymphoid cells are increased in systemic lupus erythematosus. Clin Exp Rheumatol. (2019) 37:676–9.

  • Pubmed Abstract
  • Google Scholar

• 28.

  DusterMBeckerMGnirckACWunderlichMPanzerUTurnerJE. T cell-derived IFN-gamma downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus. Eur J Immunol. (2018) 48:1364–75. 10.1002/eji.201747303

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  LuCHLaiCYYehDWLiuYLSuYWHsuLCet al. Involvement of M1 macrophage polarization in endosomal toll-like receptors activated psoriatic inflammation. Mediators Inflamm. (2018) 2018:3523642. 10.1155/2018/3523642

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  MohammadiSSaghaeian-JaziMSedighiSMemarianA. Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. Lupus. (2017) 26:1318–27. 10.1177/0961203317701842

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  IkezumiYKondohTMatsumotoYKumagaiNKanekoMHasegawaHet al. Steroid treatment promotes an M2 anti-inflammatory macrophage phenotype in childhood lupus nephritis. Pediatr Nephrol. (2020) 36:349–59. 10.1007/s00467-020-04734-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar